Childhood interstitial lung disease, known as “chILD,” is a group of rare lung conditions that affect babies, kids, and teens. All forms of chILD cause damage to a child’s lungs, so they don’t work ...

Interstitial lung disease (ILD) refers to a group of conditions that cause damage and stiffness in the lung tissue. Over time, this damage can make it harder for oxygen to move into the bloodstream.

Lisa H. Lancaster, MD: Interstitial lung disease is a rare but not uncommon disease of scaring or inflammation that occurs in a space, or potential space, between the Avella and the capillaries or ...

Please provide your email address to receive an email when new articles are posted on . Aging and tobacco smoke exposure increased the chances for interstitial lung abnormalities. These abnormalities ...

Interstitial Lung Disease: Types, Symptoms, Causes, Diagnosis and Treatments: By Shreoshree Chakrabarty Interstitial Lung Disease (ILD) refers to a group of lung disorders that cause inflammation and ...

Despite patients sharing a usual interstitial pneumonia (UIP) pattern on lung CT scans, patients with connective tissue disease-related interstitial lung disease (CTD-ILD) demonstrated a slower ...

Reviewing medical information gathered on more than 6,000 adults over a 10-year period, researchers have found that lower than normal blood levels of vitamin D were linked to increased risk of early ...

For some patients with early non-small cell lung cancer and lung scarring, stereotactic ablative radiotherapy may be a viable option, research has shown. Stereotactic ablative radiotherapy (SABR) has ...

Baylor Medicine’s Interstitial Lung Disease (ILD) program offers specialized and multidisciplinary care. We bring together a unique team of physicians of multiple sub-specialties for patients with a ...

Interstitial lung disease is a group of conditions that cause scarring in your lungs. The scarring often leads to breathing problems, which can range from mild to severe. Interstitial lung disease ...

Neil B. Minkoff, MD: Today we are discussing patient management of chronic fibrosing interstitial lung disease with progressive phenotype. I’m Dr Neil Minkoff, the chief medical officer of Coeus ...